An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression

BACKGROUND: Many patients with Parkinson’s disease (PD) experience depression. OBJECTIVE: Evaluate pimavanserin treatment for depression in patients with PD. METHODS: Pimavanserin was administered as monotherapy or adjunctive therapy to a selective serotonin reuptake inhibitor or serotonin/noradrena...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Parkinsons Dis
Egile Nagusiak: DeKarske, Daryl, Alva, Gustavo, Aldred, Jason L., Coate, Bruce, Cantillon, Marc, Jacobi, Lori, Nunez, Rene, Norton, James C., Abler, Victor
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: IOS Press 2020
Gaiak:
Research Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7683094/
https://ncbi.nlm.nih.gov/pubmed/32804101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-202058
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak